STAT News

STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more

AstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacks

Por STAT News

1 minuto de lectura
Compartir
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas